
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. has demonstrated a positive financial trajectory, as evidenced by an operating revenue increase of 43% year-over-year, outpacing consensus expectations. The company has also raised its gross margin guidance for 2025 to a range of 76-77%, indicating improved profitability, alongside a focus on enhancing Light Adjustable Lens (LAL) volumes through strategic engagement initiatives. Furthermore, potential catalysts for future growth include an expanding LDD installed base and better utilization rates, which could enhance overall revenue and margin performance in the coming quarters.
Bears say
The financial analysis indicates a negative outlook for RxSight due to declining utilization rates of light adjustable lenses (LALs), with monthly utilization decreasing to 8.0 LALs per light delivery device (LDD) in 3Q25 from 8.7 in 2Q25 and 10.1 in 3Q24. The company's guidance for FY2026 revenue of $120-135 million reflects a decline of 11% year-over-year, which is notably below both internal and external estimates, signaling potential struggles in meeting market expectations. Additionally, declining revenue trends, including a 14% year-over-year decrease to $30.3 million in one quarter, alongside anticipated gross margin pressure due to higher inventory costs, further compound the challenges facing the company.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares